For people with certain BRCA mutations, activating the immune system could be promising treatment

(Memorial Sloan Kettering Cancer Center) Tumors with mutations in the BRCA2 cancer-predisposition gene respond better to checkpoint blockade immunotherapy than tumors with mutations in BRCA1, scientists at Memorial Sloan Kettering have found.